DETERMINANTS OF EFFECTIVE HIV COUNSELING NIH Guide, Volume 22, Number 17, April 30, 1993 PA NUMBER: PA-93-080 P.T. 34 Keywords: Drugs/Drug Abuse Social Psychology Behavioral/Social Studies/Service National Institute on Drug Abuse PURPOSE The purpose of this program announcement is to initiate and support a research program that focuses on understanding the psychological, behavioral, interpersonal, and motivational factors that enhance or retard the effectiveness of HIV counseling and testing activities in drug abusers, their sexual partners, and others at risk of HIV infection who could potentially benefit from counseling and testing activities. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This program announcement, Determinants of Effective HIV Counseling, is related to the priority area of reducing HIV transmission. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: 202/783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from minority individuals and women are encouraged. Foreign institutions are not eligible for the First Independent Research Support and Transition Awards (R29). MECHANISMS OF SUPPORT Research support mechanisms include research projects grants (R01), small grants (R03), and FIRST awards (R29). Because the nature and scope of the research proposed in response to this program announcement may vary, it is anticipated that the size of an award will vary also. RESEARCH OBJECTIVES Background Initial efforts to prevent the spread of HIV infection were a response to a public health crisis, and resource priorities were given to informing, educating, and warning rather than to evaluating the effectiveness of programs. Prevention programs began to incorporate evaluation components, using "pretest/post-test" designs and, later, randomized trials of effectiveness. Although there is now a growing body of literature comparing the effects of different HIV risk reduction counseling approaches, there is relatively little emphasis on delineating the effective components of interventions and systematically relating outcomes to the motivational, psychological, behavioral, and interpersonal development theories that form the basis of those components. Sophisticated evaluation of counseling and testing programs in relation to their theoretical underpinnings would allow for better understanding of why and for whom a particular intervention has effects. To develop intervention models more effectively that can be readily transferred to the general HIV prevention community, it is necessary to "open the black boxes" of prevention programming to understand better the mediating factors associated with success. Research is needed that examines the relationships among risk reduction outcomes, theoretical mediating variables, fidelity of implementation of prevention program, the social and environmental context in which the intervention is delivered, and the social/environmental context of the client's life. Treatment of addiction, street outreach to provide education and to facilitate entrance into drug treatment, and clinic-based counseling and testing programs continue to be the mainstays of HIV prevention activities for drug abusers, especially injection drug users (IDUs), and their sexual contacts. While most counseling and testing programs report changes in drug abuse related risk behaviors, and to a lesser degree in sexual risk behaviors, many comparisons between relatively minimal interventions and more extensive interventions based on well-known theories relevant to health behavior have not shown differential effects of the interventions. The most commonly used theories to design prevention interventions are the Health Beliefs Model, the AIDS Risk Reduction Model, and the Theory of Reasoned Action. Yet, there are other theoretical perspectives that might be usefully applied to HIV prevention efforts, such as conceptualizations of social group processes, psychotherapy/counseling, personality development, communication, motivation, and drives. Examples of variables that need to be systematically examined in HIV counseling are characteristics of the client (demographics, serostatus, psychological variables), characteristics of the message (mediators), and characteristics of the intervenor (e.g., similarity to client, race, history of drug abuse, gender, personality). The social context of the client has been examined in some studies, but it has not been examined extensively for its interaction with other variables of interest such as type of intervenor, type of message, etc. Technology for examining these issues exists in social psychology, studies of psychotherapy, communication research, and related fields. Prevention programs are often directed at people with marginal support systems and with few intrapersonal or interpersonal resources. The possibility of negative effects of HIV counseling has been examined from the viewpoint of negative affective sequelae of the intervention and short-term increases in risk behavior, but long-term studies of possible negative effects on risk behavior, psychosocial adjustment, or disease acquisition and transmission are few. Studies have not extensively examined the determinants of negative behavioral consequences of interventions in drug abusers. Program Objectives The primary objective of the Program Announcement is to understand the determinants of effectively using HIV testing and counseling as a prevention intervention in drug abusers, their sexual partners, and others at risk for HIV infection. Determinants of negative behavioral outcomes should also be examined. Risk behavior should be a primary outcome variable. In addition, other variables to be investigated should be drawn from potentially relevant theories of human behavior and development, and these should be defined, measured, and manipulated using standardized methodology. Applications would ideally include a component whereby differential and mutually exclusive outcomes predicted by theories of psychological development or psychological change are examined and related to risk reduction. For example, counseling theory would suggest that a counselor who reveals strong, current ambivalence about facets of his or her own development, upbringing, or behavior may "reenact" those issues in provision of HIV risk reduction counseling, thereby failing to achieve effective risk reduction. An outcome inconsistent with this theory would be that the ambivalence would not be evidenced in the interpersonal processes in the counseling or would not be related to behavioral outcomes. Applications that attempt to evaluate the effectiveness of a specific intervention and advance theoretical understanding will be considered responsive to the intent of this announcement. Although prospective studies are encouraged, retrospective studies that examine outcome, process, and social context variables of programs with documented successful impact on risk behaviors will also be welcomed. If the study is planned for a drug treatment program, the proposed intervention(s) should consist of HIV counseling and testing activities rather than the treatment of drug abuse itself. If an applicant elects to use an out-of-treatment sample, the application should provide details on the logistics of how adequate information could be collected. Consideration could be given to use of treatment samples to fully explore issues of interest while out-of-treatment samples are used to replicate and generalize where feasible. Prospective studies as currently envisioned should incorporate: (1) theoretical and operational definition of relevant constructs, with attention to use of consistent, reliable, and valid measures of independent and dependent variables; (2) random assignment of clients to counselors or intervention; (3) study of client cognitions, affects, perceptions, and behaviors; (4) study of counselor cognitions, affects, perceptions, and behaviors; (5) statistical or design methods for accounting for and explaining the effects of counselor training and technique; and (6) sufficiently thorough description of an intervention to permit replication, with documentation of the fidelity with which the intervention is implemented. The specific areas of interest include, but are not limited to: a. Factors that create effective HIV testing and counseling processes from both the client's and counselor's perspective. b. Factors that produce negative outcomes in HIV testing and counseling processes from both the client's and counselor's perspective. c. Why some risk reduction interventions and intervenors (counselors) are effective and some are not. d. Enhanced methodology for measuring relevant risk related psychosocial variables. e. Delineation of the circumstances in which HIV counseling and testing has a positive impact, and those in which it has a negative impact. f. Clarification of the relative contribution of the counseling component to outcomes of "counseling and testing programs," and, conversely, clarification of the relative contribution of the testing component to outcomes. g. Factors that predict and prevent testing refusal, non-return for results, deficient learning of critical information, denial of vulnerability, concealment of attitudes or risk behaviors from counselors, and failures to develop resistance to risk behavior relapse. h. Interactions between HIV testing and counseling and drug abuse treatment. i. Sexual and drug risk behavior interactions that decrease or increase overall risk. j. Factors related to counseling influencing the risk behaviors of those who are HIV infected. k. Variables that, when studied in the context of HIV counseling and testing, have implications for advancing theoretical understanding of human behavior and behavior change processes. Special Requirements Grants funded under this program announcement are subject to the requirements of 45 CFR 46, Protection of Human Subjects. If the proposed research includes children as the subject population described in 45 CFR 46, subpart D, special human subject considerations apply. These regulations are available from the Office for Protection from Research Risks (OPRR), National Institutes of Health, Building 31, Room 5B63, Bethesda, MD 20892, telephone 301/496-8101. Because of the AIDS relevance of this research, applicants should obtain from their institutional review board (IRB) a copy of the "Guidance for Institutional Review Boards for AIDS Studies," which was disseminated from the OPRR on December 16, 1984. If a copy is not available locally, one may be obtained from OPRR at the address and number above. Because of the expedited schedule of review and award for these applications, applications from organizations having an approved Multiple Project Assurance of Compliance on file with the OPRR must be accompanied by certification of IRB approval. The latest date of approval by the IRB of the proposed activities must be not earlier than one year prior to the receipt date called for in this announcement. If appropriate certification of IRB approval is not provided with the proposal at the time of submission, the application will be considered incomplete and returned to the applicant without review. If the applicant organization does not have on file with OPRR an approved Multiple Project Assurance of Compliance, the applicant organization, by the signatures on the Face Page of the application, is declaring that it will comply with 45 CFR 46 by establishing an IRB and submitting an Assurance of Compliance and certification of IRB approval within 30 days of a specific request from OPRR. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the AIDS receipt dates indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone: 301/710-0267. The title and number of this announcement must be typed in Item 2a on the face page of the application. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW PROCEDURES Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit by an initial review group in accordance with standard review procedures. AWARD CRITERIA Applications will compete for available funds with all other applications recommended for further consideration by the appropriate National Advisory Council. The following will be considered in making funding decisions: o Quality of the proposed project as determined by the peer review; o Availability of funds; and o Program balance among research areas of the announcement. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Applicants interested in studies relevant to drug abusers and their sexual partners may direct inquiries regarding programmatic issues to: William C. Grace, Ph.D. Division of Clinical Research National Institute on Drug Abuse 5600 Fishers Lane, Room 11A-33 Rockville, MD 20857 Telephone: (301) 443-1801 Inquiries regarding fiscal matters related to drug abuse relevant studies may be directed to: Mrs. Shirley Denney Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8A-54 Rockville, MD 20857 Telephone: (301) 443-6710 Applicants interested in other populations, may direct inquiries regarding programmatic issues to: M. Isabel Fernandez, Ph.D. Office on AIDS National Institute of Mental Health 5600 Fishers Lane, Room 15-99 Rockville, MD 20857 Telephone: (301) 443-7281 Inquiries regarding fiscal matters related to NIMH applications may be directed to: Diana Trunnell Grants Management Section National Institute of Mental Health 5600 Fishers Lane, Room 7C-23 Rockville, MD 20857 Telephone: (301) 443-3065 AUTHORITIES AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of the Public Health Service Act, Section 301, and administered under PHS grants policies and Federal Regulations at 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Grants must be administered in accordance with the PHS Grants Policy Statement (rev. 10/90). .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||